Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)Johan Maertens, Julien De Greef, Anne Thiebaut‐Bertrand et al.|Leukemia|2019Cited by 185
Genetic alterations and MRD refine risk assessment for <i>KMT2A</i>-rearranged B-cell precursor ALL in adults: a GRAALL studyRathana Kim, Emmanuelle Clappier, Françoise Huguet et al.|Blood|2023Cited by 29
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemiaYves Chalandon, Hervé Dombret, Isabelle Plantier et al.|Blood|2024Cited by 28
Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2Nicolas Boissel, Hervé Dombret, Mathilde Hunault et al.|Blood|2021Cited by 23
Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B StudyNicolas Boissel, Hervé Dombret, Laurence Sanhès et al.|Blood|2022Cited by 23